A Budget Impact Analysis (Bia) Of The Use Of Paricalcitol For The Treatment Of Secondary Hyperparathyroidism (Shpt) In End Stage Renal Disease Patients

Value Health. 2014 Nov;17(7):A467. doi: 10.1016/j.jval.2014.08.1313. Epub 2014 Oct 26.
No abstract available